| Literature DB >> 30633902 |
Kristopher R Genschmer1, Derek W Russell1, Charitharth Lal2, Tomasz Szul3, Preston E Bratcher4, Brett D Noerager5, Mojtaba Abdul Roda3, Xin Xu6, Gabriel Rezonzew2, Liliana Viera7, Brian S Dobosh8, Camilla Margaroli8, Tarek H Abdalla9, Robert W King9, Carmel M McNicholas10, J Michael Wells11, Mark T Dransfield12, Rabindra Tirouvanziam8, Amit Gaggar13, J Edwin Blalock14.
Abstract
Here, we describe a novel pathogenic entity, the activated PMN (polymorphonuclear leukocyte, i.e., neutrophil)-derived exosome. These CD63+/CD66b+ nanovesicles acquire surface-bound neutrophil elastase (NE) during PMN degranulation, NE being oriented in a configuration resistant to α1-antitrypsin (α1AT). These exosomes bind and degrade extracellular matrix (ECM) via the integrin Mac-1 and NE, respectively, causing the hallmarks of chronic obstructive pulmonary disease (COPD). Due to both ECM targeting and α1AT resistance, exosomal NE is far more potent than free NE. Importantly, such PMN-derived exosomes exist in clinical specimens from subjects with COPD but not healthy controls and are capable of transferring a COPD-like phenotype from humans to mice in an NE-driven manner. Similar findings were observed for another neutrophil-driven disease of ECM remodeling (bronchopulmonary dysplasia [BPD]). These findings reveal an unappreciated role for exosomes in the pathogenesis of disorders of ECM homeostasis such as COPD and BPD, providing a critical mechanism for proteolytic damage.Entities:
Keywords: BPD; COPD; ELA-2; elastase; exosomes; extracellular matrix; extracellular vesicles; inflammation; lung disease; microparticles; neutrophil
Mesh:
Substances:
Year: 2019 PMID: 30633902 PMCID: PMC6368091 DOI: 10.1016/j.cell.2018.12.002
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582